The ‘AI Gods’ Spending As Much As They Can On AI Tokens

At companies including Meta, Nvidia and Databricks, engineers are celebrated the more they spend to use AI. “This is easy money,” Meta CTO Andrew Bosworth said. “No limit.”

Hong Kong Property Tycoon Peter Lee Leads $300 Million Round In U.S. Battery Startup

EnerVenue develops grid-scale energy storage systems, which are critical to AI data centers.

Can Surging Gas Prices Reverse U.S. EV Sales Slump?

This week’s newsletter also looks at why the world may be on the verge of a bigger oil shock than in 1973 and investor Tom Steyer’s plan to cut California energy prices

NASA Is Planning A Nuclear-Powered Trip To Mars

Why nuclear makes sense for the Red Planet. Google’s new memory math for AI. Why video games help you sleep. All that and more in this week’s edition of The Prototype.

This Crypto Billionaire Wants To Use The Human Brain As A Blueprint For AI

Ripple and Stellar founder Jed McCaleb wants to build AGI by studying how the brain learns—then translating those rules into AI.

Inside The Race To Sell OnlyFans

OnlyFans has been a money-printing machine for its secretive billionaire owner Leonid Radvinsky. Investors were puzzled by an obscure debt fund’s pitch to buy him out, until they learned of his terminal cancer diagnosis.

These Hackers Launched A ‘Nightmare’ Attack On AI Developers

TeamPCP hackers say AI helped them launch a devastating spree of attacks. But they wouldn’t have succeeded if developers’ security hadn’t been so weak in the first place.

The Iran War Could Make Your Next MRI More Expensive

In this week’s edition of InnovationRx, we look at a serial entrepreneur’s effort to build an FDA-approved AI doctor, Pfizer’s lyme disease vaccine, and more.

Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny

Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions by some of India’s biggest pharma companies.